Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Smallpox Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT

NCT00038987
View directory record Official record
Conditions
Smallpox
Interventions
Wetvax (APSV)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
4
States / cities
Oakland, California • Iowa City, Iowa • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

NCT01144637
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 40 Years
Enrollment
4,005 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®

NCT00042094
View directory record Official record
Conditions
Smallpox
Interventions
Cell-Cultured Smallpox Vaccine compared to Dryvax®
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

NCT00001043
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
gp160 Vaccine (Immuno-AG)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
2
States / cities
St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Combination Study With MVA BN and Dryvax

NCT00082446
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox

NCT00053742
View directory record Official record
Conditions
Healthy
Interventions
Modified Vaccinia Virus Ankara TBC-MVA
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ACAM 3000 MVA at Harvard Medical School

NCT00133575
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine, Placebo, Live vaccinia virus vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

NCT00316602
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IMVAMUNE
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 40 Years
Enrollment
632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

NCT00857493
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
56 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Orlando, Florida • Iowa City, Iowa • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

NCT01827371
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
435 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
6
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

NCT02474589
View directory record Official record
Conditions
Smallpox
Interventions
tecovirimat, Placebo
Drug · Other
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
11
States / cities
Mobile, Alabama • Redding, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 1:01 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

NCT00053508
View directory record Official record
Conditions
Smallpox
Interventions
ACAM1000, vaccinia virus (calf lymph) smallpox vaccine: Dryvax
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 29 Years
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
3
States / cities
Orlando, Florida • Rochester, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

NCT00053482
View directory record Official record
Conditions
Smallpox
Interventions
ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
28 Years and older
Enrollment
357 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
3
States / cities
Lenexa, Kansas • Springfield, Missouri • Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers

NCT00002261
View directory record Official record
Conditions
HIV Infections
Interventions
Smallpox Vaccine, HIVAC-1e, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 26, 2007 · Synced Oct 22, 2026, 1:01 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

NCT04957485
View directory record Official record
Conditions
Smallpox
Interventions
Tecovirimat, Smallpox and Mpox Vaccine, Placebo
Drug · Other
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 42 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 1:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

NCT00282581
View directory record Official record
Conditions
HIV Infections, Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

NCT02038881
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VHA Clinicians and Bioterror Events: Interactive Web-based Learning

NCT00123396
View directory record Official record
Conditions
Smallpox, Anthrax
Interventions
BioCASES and BioTESTS
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 22, 2026, 1:01 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

SIGA-246 to Treat Smallpox

NCT00303225
View directory record Official record
Conditions
Vaccinia
Interventions
Vaccine: SIGA-246
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

APSV in Vaccinia Naive Adults

NCT00050518
View directory record Official record
Conditions
Smallpox
Interventions
Aventis Pasteur Smallpox Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2003
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Dressing Preparations for Smallpox

NCT00063856
View directory record Official record
Conditions
Smallpox
Interventions
Wetvax (APSV)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

NCT05935917
View directory record Official record
Conditions
Smallpox
Interventions
Brincidofovir
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

MVA Post-Event: Administration Timing and Boost Study

NCT00437021
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
7
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 22, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Expanded Dryvax Dilution Study in Previously Vaccinated Adults

NCT00050505
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
32 Years to 70 Years
Enrollment
927 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
7
States / cities
Oakland, California • Stanford, California • Torrance, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 22, 2026, 1:01 AM EDT